LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results